Podcast Karim Chamie, MD @UclaUrology #ASCO22 #OncoTwitte...

Podcast Karim Chamie, MD @UclaUrology #ASCO22 #OncoTwitter Phase 2/3 QUILT-3.032 Trial
8 months 63 Du kan ikke administrere denne video

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract - Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).


Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that intravesical treatment of N-803 with BCG induced full remission in all patients, with no recurrences over the 24-month study period. Pembrolizumab was licensed in 2020 after a single arm phase 2 trial of 96 patients yielded a 41 percent complete response (CR). We present findings from a 160-person open-label, three-cohort multicenter study (QUILT 3.032) of intravesical BCG with N-803 in patients with BCG-unresponsive high-grade NMIBC (NCT03022825).


In accordance with the normal induction/maintenance therapy regimen, all treated patients received intravesical N-803 plus BCG. Cohort A (CISprimary )'s outcome is the occurrence of CR of CIS at any time. Disease-free rate (DFS) at 12 months is the primary goal for Cohort B (Papillary).


We have so far enrolled 160 patients (83 CIS, 77 Papillary). The whole population has a median age of 72.3 years, an 81 percent male population, and a mean number of past TURBTs of 4. The average number of past BCG injections was 12. CIS patients had a CR rate of 71% (59/83), with a median duration of CR of 24.1 months in responders; 91% avoided cystectomy, and 96% had 24 month bladder cancer specific progression free survival (defined as progression to MIBC). Papillary patients had a DFS incidence of 57 percent at 12 months, 48 percent at 24 months, and 95 percent avoided cystectomy. The median time to cystectomy in responders (N = 4) is 12.9 months compared to 7.8 months in non-responders (N = 8), representing a 5.1 month delay in cystectomy. N-803 action is restricted to the bladder, according to PK data. Low grade treatment-related AEs (grade 1-2) include dysuria (22%), pollakiurua (19%), hematuria (18%), weariness (16%), and urgency (12%); all other AEs were reported at 7% or less. There were no treatment-related grade 4 or 5 adverse events. There were no SAEs that were deemed treatment-related. There have been no immune-related SAEs seen.


At 2 years, there is a 99 percent bladder cancer specific overall survival in 160 patients with BCG-unresponsive NMIBC. In CIS patients, the CR rate was 71%, with a median duration of response of 24.1 months, while the DFS rate was 53% at 18 months. With a two-year follow-up, more than 90% of patients avoided cystectomy. N-803+BCG outperforms other current intravesical and systemic alternatives for BCG-unresponsive NMIBC in terms of efficacy and safety. NCT03022825 is the clinical trial number.